Objectives

- Recognition of what might and what might not be skin cancer
- What can I handle–what should I refer?
- Post diagnosis/post treatment protocols.
- Who do I refer to?
- “Lots” of busy slides for home/office/later perusal.
- And, of course, derm pictures.
• The first commercially feasible synthesis of prednisone was carried out in 1955 in the laboratories of Schering Corporation, which later became Schering-Plough Corporation, by Arthur Nobile and coworkers.

#ChooseKnowledge #POMA19

(One of many)
1st rule of dermatology:

If you know what it is, why touch it?
If you don't know what it is, don't touch it.

But......

#ChooseKnowledge #POMA19

Cancer Facts and Figures 2018.
American Cancer Society
Wehner MR, Chren MMA, Nameth D, et al
International prevalence of indoor tanning: a systematic review and meta-analysis
-- JAMA Dermatology 2014

US of A, N and W Europe and Australia

Each year

Estimated 452,796 cases of BCC/SCC and 11,374 cases of MM attributed to indoor tanning
Estimated 362,941 cases of lung cancer attributed to smoking

Whys and Wherefores

• Cutaneous cancers account for >50% of all malignancies in U.S.
  • 3-4 million new cases of BCC and SCC annually

• UV radiation (UVR) in sunlight is the primary etiology for all skin cancers

#ChooseKnowledge #POMA19

Environmental Agents Associated with the Development of Human Skin Cancer

• UV radiation
• Cigarette smoke
• Soot
• Coal tar, pitch
• Petroleum Oils
• Arsenic
• PCB
• Dry-cleaning
• Fiberglass
• Paint
• Nitrogen mustard
• Immunosuppressants
• Ionizing radiation

General population: BCC, SCC, MM
Smokers: SCC
Chimney Sweeps: SCC
Stalk workers: SCC
Machinists, textile workers: SCC
Agricultural workers: BCC, SCC
Petrochemical workers: SCC
Dry cleaners: BCC
Insulators: BCC
Porcine patients: BCC, SCC-MM
CTCL patients: SCC
Transplant patients: BCC, SCC
Various skin disorders: BCC, SCC

POMA 111th Annual Clinical Assembly & Scientific Seminar
May 1-4, 2019
### Ultraviolet Radiation
- Causes DNA damage—leading to mutations
- Allows clonal expansion of malignant cells with altered signaling pathways providing a survival advantage
- Acts as an immune suppressant

#ChooseKnowledge #POMA19

### Cigarette Smoke
- Cigarette and pipe smokers have an overall twofold increased risk for cutaneous SCC

#ChooseKnowledge #POMA19

### Other tidbits
- Soot
  - Described in 1775 with chimney sweeps and scrotal carcinoma
- Petroleum products
- Particularly SCC
- Fiberglass and dry-cleaning chemicals
- BCC
- Arsenic exposure
  - BCC, SCC as well as internal malignancies
  - Occupational exposure—agricultural pesticides, sheep/cattle dip, mining, smelting, glass works
  - More insidious exposure—contaminated water or shellfish
  - Arsenic exposure + UVR act as cocarcinogens—increased frequency and size of lesions

#ChooseKnowledge #POMA19
And…

- PUVA
  - Less used today especially with introduction of biologics
  - Long lasting effects—even after d/c light therapies
- Nitrogen mustard
  - Used for CTCL
- Immunosuppressants/transplant patients
  - Transplant patients risk of developing SCC about 100 times that of general population
  - Usually start to develop about 3-5 yrs post transplant:
    - SCC - 100 fold increase
    - BCC - 4 fold increase
    - MM - 2 fold increase
    - Merkel cell - 24 fold increase

Preventative measures

- Sunscreen use
- Avoidance of “middle-of-the-day” outdoor activities
- Protective clothing
  - Hat
  - Shirt
  - Sunglasses

Lifetime risk

- Effects of UVR causing NMSC is cumulative, therefore with reducing lifetime UVR exposure we would expect to reduce risk of developing NMSC
- Melanoma probably more linked to intense childhood exposure, but not completely so.
“Skin Cancer Overview”
Richard E. Johnson, DO

Let’s get started

• Basal Cell—BCC
• Squamous Cell—SCC
• Melanoma—MM

73yo male
left lumbar psoas

• A. Tinea corporis
• B. Psoriasis
• C. BCC
• D. Nummular eczema
• E. Lyme
63yo female
left mid-tibia

A. Malignant melanoma
B. SCC
C. BCC
D. Erythema nodosum
E. Traumatized seborrheic keratosis

#ChooseKnowledge

25

47yo female

A. Malignant melanoma
B. Pigmented basal cell
C. HSV scar
D. Acne excoriated
E. Contact dermatitis

#ChooseKnowledge

26

57yo male

A. “I picked a pimple”
B. BCC
C. Welding burn
D. “I nicked myself while shaving”
E. Melanoma

#ChooseKnowledge

27
53yo male

A. BCC
B. Granuloma annulare
C. Sebaceous hyperplasia
D. Ruptured cyst
E. Scar

87yo male

A. Amelanotic melanoma
B. BCC
C. SCC
D. Actinic keratosis
E. “scar from my glasses”

Subtypes

- Nodular
- Pigmented
- Rodent ulcer
- Superficial spreading
- Morpheaform/sclerosing
Basal Cell Carcinoma

- **BCC most common** form of human cancer
  - 75% of NMSC and about 25% of all cancers
  - Detected and treated early - highly curative
  - Generally older than 50yo, but increasing in younger population

- **Risk factors**
  - UV, especially UVB
  - Regular exposure (occupational) vs intermittent i.e. weekend warrior which may be more damaging
  - Light hair and eye color
  - Northern European ancestry
  - Inability to tan
  - Patient with BCC history = 3 fold increase risk of melanoma
  - Check your patients’ backs at every visit

#ChooseKnowledge
#POMA19
Presentation

Rule out skin cancer

- ANY friable, non-healing lesion
- ANY "it was there, then healed, and now it's back" lesion
- ANY "it's only a curling iron burn, I did it several weeks ago"
- (almost) ANY "I picked a pimple, and now it won't heal"

Pearly, translucent, telangiectasiae, ulceration, rolled borders

#ChooseKnowledge
#POMA19

“I just burnt myself with curling iron
(3 weeks ago)

#POMA19
#ChooseKnowledge

Biological behavior

- Generally slow growing with local extension—rare mets
  - One study had rate of mets of 0.0028–0.55%
- Without treatment: invasion of subcutaneous tissue down to bone
- Anatomic fusion plates, watch for tumor progression
  - Nose/alar to cheek junction
  - Retroauricular areas

#POMA19
#ChooseKnowledge
Diagnosis

- Physical exam—visual diagnosis
  - ....but BCC vs amelanotic melanoma

- Biopsy
  - For diagnosis
  - For billing
    - Can’t bill for BCC without a path report—cryosurgery treatment (=D48.5)
  - For patient’s cancer policy
    - Cryosurgical treatment or disquamoid treatment
Skin Cancer Overview
Richard E. Johnson, DO

- Biopsy, cont’d
  • For treatment
    - Your office
    - Referral
      - Radiation will need biopsy before they treat
      - Mohs surgeon

  Consider patient costs:
  biopsy one day, come back another day for treatment
  travel, off work, copays
  biopsy then refer
  why not just refer

#ChooseKnowledge #POMA19

Patient-initiated
- i.e. pt’s reason for visit

Physician-initiated
- i.e. incidental finding

I don’t like it
Changes noted…

Cosmetic
- bx cost
- tx cost
- path fees
- scar
- results you want?

Refer
Reassure
Pt returns
refer
bx or tx

Change
- size
- shape
- color
- symptoms

Obvious diagnosis
Not sure of
diagnosis, but…

bx – tx right then
refer
bx tx refer

#ChooseKnowledge #POMA19

Biopsy

- Shave vs punch
  - “new” 2019 biopsy codes—tangential vs punch
  - Time/cost/effort—what are you trying to accomplish
  - Punch if BCC in a scar vs scar tissue is involved

  OR

- Just treat it:
  - Shave, curettage, and electrodessication

#ChooseKnowledge #POMA19
Treatment

- Biopsy then treat or just treat
  - Physician comfort level/skill
  - Patient comfort level
  - Consider:
    - recurrence rate
    - preservation of function
    - Patient or family expectations
    - Side effects of treatment

#ChooseKnowledge
#POMA19

Treatment options

- Cryosurgery
  - Thermocoupler vs double freeze thaw
  - More recurrence potential
    - Larger or thicker lesions
  - “very good” for superficial spreading BCC
    - Multiple lesions can be treated at one visit

#ChooseKnowledge
#POMA19

Treatment options

- Topical
  - Imiquimod
    - FDA approved for superficial BCC on trunk, neck, & extremities
    - Side effects expected—patient counselling is a must
    - Dosing regimens
  - 5-fluorouracil
    - Used more for actinic keratoses and superficial SCC than for BCC
    - Works by causing inflammation and subsequent healing
    - Side effects expected—patient counselling is a must
    - Dosing regimens
Treatment options

- **SCE x 3**
  - Shave, curettage, and electrodessication
  - Lesions <1cm cure rates of 98-99%
  - 1-2cm cure rates of 95-96%
  - >2cm cure rates about 85%
  - With recurrent treatments cure rates go down
  - N.B. with SCE x 3 as biopsy and subsequent treatment:
    - Can’t bill a biopsy and a treatment—just bill the treatment
    - Path report may verbalize “+” margins, can be confusing when patient or other physician gets path report—needs another procedure?

- Treatment options
  - SCE x 3 plus imiquimod post-op for a month
    - For field treatment of the area

- Treatment options
  - Photodynamic therapy
    - Two-part treatment
      - Application of photosensitizer followed by 1+++hrs exposure to light
      - May be preceded by light curettage of the BCC(s)
      - Non-responders are retreated in about a week
      - Higher recurrence rates than with other modalities
      - Post-treatment adverse events include:
        - Photosensitivity—need for light avoidance and photoprotection for 48hrs
        - Erythema
        - Crustiness
        - Tenderness
### Treatment options

- **Surgical/cold steel**
  - Elliptical/flap/grafts
  - Recommendation for 4mm margin of uninvolved skin
  - With smaller (<5mm) lesions recurrence rates for surgery vs SCE x 3 very similar

- **Mohs micrographic surgery**
  - Very low recurrence rates
  - “Better” for recurrent lesion
  - “Better” for morpheaform lesion

- **Radiation**
  - Time consuming
  - “Must” have biopsy first
  - Permanent alopecia
  - With recurrence, may be a more aggressive tumor

### Incompletely excised BCC

- **How was original tumor treated**
  - With SCE x 3 margin will be “+”

- **Patient age/medical condition**
  - Watch and wait
    --- Study from the 1960’s reported 50-70% of incompletely excised BCC’s don’t/won’t recur

- **Send for Mohs or radiation therapy**
  - #ChooseKnowledge
  - #POMA19
Biological therapies

• Metastatic BCC are quite rare: 0.0028%–0.55%

Follow-up recommendations

• With diagnosis of BCC (as well as SCC and MM for that matter)
  • Yearly screening
  • Look at your patients’ backs!!
  • Recommend self exams at home
  • Discuss sun/UVR protection
    • Patients and family members and anyone who will listen
    • NO TANNING BOOTH

52

53

54
Squamous Cell Carcinoma (SCC)

- BCC’s start de novo, SCC’s start from precursors: AK’s and Bowen’s
- BCC’s rarely metastasis, SCC can range from easily managed to local invasive to highly infiltrative and lethal
- After dx of SCC, patient has 45-50% cumulative risk of developing another NMSC in next 3-5 yrs.
- Watch your patients—look at backs and ears and posterior necks
- Generally more likely in men: women with longer hair and lipstick offers some protection

SCC

- Squamous cell carcinoma (SCC) is the second most common form of skin cancer.
- More than 1 million cases of SCC are diagnosed in the U.S. each year, resulting in more than 15,000 deaths.
- Organ transplant patients are approximately 100 times more likely than the general public to develop squamous cell carcinoma.

Risk factors

- UV radiation
- Cigarette smoke
- Coal tar, pitch
- Petroleum Oils
- Arsenic
- PCB
- Dry cleaning
- Fiberglass
- Perosil
- Nitrogen mustard
- Immunosuppressant
- Ionizing radiation

Risk factors for SCC:
- General population BCC, SCC, MM
- Smokers SCC
- Chimney Sweeps SCC
- Steel workers SCC
- Machinists, textile workers SCC
- Agricultural workers BCC, SCC
- Pesticide workers HN
- Dry cleaners BCC
- Insulators BCC
- Porcelain patients BCC, SCC
- CTCL patients SCC
- Transplant patients BCC, SCC
- Various skin disorders BCC, SCC
Risk factors

- UVR is #1
- PUVA
- Scar cancer

A 46 years male with 3 years history of ulceration and bleeding in right axilla. He had sustained scald burns at the age of 3. Biopsy confirmed it to be squamous.

- Chronic inflammatory conditions
- Venous ulcers
- Snake bite ulcers
- DU
- Oral lichen planus
- Lichen sclerosus et atrophicus
- Hailey-Hailey disease (benign familial pemphigus)
- Necrobiosis lipoidica

- Vaccination scars—BCC more likely than SCC
- HPV

---

---

---

---
Prevention

• Same as with BCC
• Life-long UV exposure protection
• No tanning booth
• Treatment of precursor lesions
  • Treat because of what they can do, not necessarily what they will do
  • Time line discussion—Pirates stadium analogy
• Smoking cessations
• Condoms
• Decreased alcohol consumption

Clinical manifestations

• Sun-exposed areas most common
• Solitary lesions arising in precursor lesions
• Immunocompromised patients/transplant patients may develop eruptive SCC’s

Actinic keratoses

• Rough sandpaper feel—feel them vs see them
• They may come and go for weeks, months, or years
  • Watch for the ones that stay, are symptomatic, and/or grow
• Bowen’s—SCC in situ
  • Usually solitary, sharply demarcated and scaly
  • if dc, pruritus, eczema, SCC
  • Generally NOT symptomatic
  • Generally more in advanced age patients
Bowen’s disease—SCC in situ

Treatment

- Cryosurgery
- Photodynamic therapy
- Topical
  - Imiquimod vs 5-FU
- SCE
- Surgery
SCC of the keratoacanthoma type

KA's:
• Usually solitary
• Rapidly growing

Keratoacanthoma

Keratoacanthoma

POMA 111th Annual Clinical Assembly & Scientific Seminar
May 1-4, 2019
**SCC**
- Firm with crustiness, keratotic feel/look
- Flesh-colored or pink/red
- May be pigmented
- “Ratty” looking
- AK to SCC conversion—lesion now painful with minimal touch

**Metastatic risk**
- < 2cm has overall less risk—about 1%
- 2.5cm about 10% risk
- >5cm about 15% risk
- Generally SCC arising in actinically damaged skin has low risk of mets—4-5%
- Anatomical site:
  - Ear ~20% recurrence potential
  - Lip ~14% mets risk
  - Scar SCC all areas—up to 40% mets risk

**Treatment**
- Pretty much same as for BCC
- 5-FU use
  - BID x 1 month vs once daily for one week on (+/-), one week off (+/-)
Follow-up

• Same as for BCC
• At least yearly in office
  • Remind patients that more frequent if they see something
• Regular self-exams at home!!
• Lymph node assessment

Malignant melanoma

• While most cancers have shown both decreased incidence and mortality over the past several decades, the incidence of melanoma has continued to grow. Mortality has only recently stabilized in US and other countries
• Steep rise in men >60yo and in lower socioeconomical areas
• For any given age and across all ages, men have poorer survival than women
• Melanoma incidence is increasing at a faster rate than any other preventable cancer in the US
An estimated 178,560 cases of melanoma will be diagnosed in the U.S. in 2018:
- 87,290 cases will be in situ (noninvasive),
- 91,270 cases will be invasive

An estimated 9,320 people will die of melanoma in the U.S. in 2018:
- 5,990 will be men
- 3,330 will be women.

Historically:
- Men trunk, head and neck
- Women extremities
- Don’t count on it! If and where there’s skin….

Most common location: skin

At-risk populations
- Childhood cancer survivors (predominantly treated with radiation) should be offered yearly body exams
- Organ transplant patients more commonly see SCC than MM, but are at a higher risk for MM than general population
- HIV patients at higher risk than general population
- Parkinson’s patients seem to be at a higher risk. Ongoing studies looking into this
- Even L-dopa containing meds have "increased risk for MM" in package insert
- Indoor tanning/artificial sunlamps
  - Increased risk with increase years of use/hours of use per session and number of sessions
  - Minnesota study: ever-users vs never-users: 4X increased risk of developing MM
Skin Cancer Overview
Richard E. Johnson, DO

On average, a person’s risk for melanoma doubles if he or she has had more than five sunburns.

The estimated five-year survival rate for patients whose melanoma is detected early is about 99 percent in the U.S.

The survival rate falls to 63 percent when the disease reaches the lymph nodes and 20 percent when the disease metastasizes to distant organs.

ABCD’s and E’s

- Asymmetry
- Border
- Color
- Diameter
- Evolution

Considerations

- Ugly ducking sign
- Mutual birthday suit body exams
- Change the clocks twice a year—self exams twice a year

Men >60yo more likely to see PCP than dermatologist.

------------ get in the habit of looking at your patients
**More considerations**

- Recent study indicates that less than 1/3 of MM arise in an existing mole
  - I.e. 70% just show up
  - Get to know your moles
  - Selfies, for comparison

*ChooseKnowledge*  
#POMA19

---

**Melanoma types**

- Lentigo maligna
- Superficial spreading
- Nodular
- Acral lentiginous
  - Subungual variants
- Amelanotic

*ChooseKnowledge*  
#POMA19

---

**Lentigo maligna melanoma**

- Almost exclusively on sun-exposed areas of head and neck
  - Nose and cheeks most common sites
- Usually "older" patients
  - Uncommon before age 45
- Macular, irregular borders and color variations
- May become quite large

*ChooseKnowledge*  
#POMA19
Lentigo maligna melanoma

Don't let this happen!
- >10 year history
- Patient in office for "other" issues
- Not concerning to patient
  - "It's okay, I've seen 3 physicians for this and they say it's ok"

Superficial spreading melanoma
- Most common type of melanoma
- Legs of women and upper back of men… but
- Usually 50-60yo
- Irregular notched/scalloped borders with variations of color
- Slightly to definitely palpable
Skin Cancer Overview
Richard E. Johnson, DO

1 day old male
left medial knee

nope

Superficial spreading melanoma
Nodular melanoma

- Second most common variant.
- “Rapid” evolution, often arising over several weeks/months.
- More common to develop de novo than in pre-existing lesion
  - Patient/Family member observation
  - Get to know your moles
- May resemble common hemangioma, pyogenic granuloma, blue nevus, or pigmented BCC

#ChooseKnowledge

Acral lentiginous melanoma

- Most common form of MM in dark skinned patients
  - 60-70% of MM in African American
  - 10-40% of MM in Asian
  - Only 2-8% of MM in light-skinned/Caucasian patients
- Palms and soles of feet
- Subungual sites
  - Hutchinson’s sign
  - Often painful
  - May have history of trauma
  - Subungual hematomas, if acute try puncturing nail to drain it
Other variants

- Mucosal
  - Oral, vaginal wall, rectal
- Retinal

#ChooseKnowledge #POMA19

Classification and Staging

- Treatment
- Prognosis
- Follow-up

#ChooseKnowledge #POMA19

100 101 102
Biopsy/treatment

- Biopsy critical
  - Depth of lesion helps with staging/prognosis/treatment/follow-up
  - Excisional biopsy
  - Saucerization
  - Punch/incisional
    - Miss the “important stuff”

#ChooseKnowledge #POMA19

Treatment

- Surgical
  - Less time between biopsy and excision = better prognosis

Compared with stage I melanoma patients treated within 30 days of being biopsied, those treated 30 to 59 days after biopsy have a 5 percent higher risk of dying from the disease, and those treated more than 119 days after biopsy have a 41 percent higher risk.


#ChooseKnowledge #POMA19
Treatment

- General surgeon vs surgical oncologist
  - Where do you live?

- Surgical margins based on depth of lesion
  - In situ: 0.5cm (0.8-0.9)
  - ≤ 1.0cm: 1.0cm
  - > 1.0-2.0cm: 1-2cm
  - > 2.0cm: 2cm

Sentinel lymph node biopsy

- Usually for MM depths >1.0cm
  - With 0.8cm - 1.0cm consider

- With <0.8mm with adverse features:
  - Ulceration, lymphovascular invasion, and/or high mitotic rate in setting of younger age

- Reasons NOT to perform SLN Bx:
  - Advanced age
  - Poor functional status
  - Comorbid conditions that portend a short life expectancy or preclude general anesthesia or subsequent treatments

Baseline and follow-up recommendations (dermatologist vs oncologists)

- No imaging or lab studies for asymptomatic patients with new stage 0-II primary MM (tumor thickness from in-situ to >4mm but no nodes)
- Imaging and labs for specific symptoms and/or mets noted
- Dermatology "work group": no labs necessary for asymptomatic MM patients
- Oncology protocol:......

Oncology collaboration (I defer to oncology with >1mm lesions)
- High risk IIB (>4mm w/o ulceration) or IIC (>4mm w/ulceration)
- Patients with positive SLN bx
Non-surgical Treatments

- For melanoma in situ or lentigo maligna melanoma
  - Characterized by:
    - Larger tumors
    - Sun-exposed skin of face, scalp and ears of older patients
    - May be poor surgical candidates
    - Histological margins with atypical melanocytic hyperplasia
  - Must discuss possible treatment limitations of topical treatment
    - Underestimating lesion that may reflect advanced extension—potential invasive MM

#POMA19 #ChooseKnowledge

Radiation therapy not recommended as first line therapy
- May be used as adjunctive therapy in high risk MM
- Used mostly outside USA

#POMA19 #ChooseKnowledge
Melanoma and pregnancy

<table>
<thead>
<tr>
<th>Table VIII.</th>
<th>Reccomendations for management of CM and pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma and pregnancy</td>
<td>Table VIII.</td>
</tr>
</tbody>
</table>

Melanoma and pregnancy

Pregnancy recap...

- Dx during pregnancy does not alter prognosis nor outcome for woman
  - However, work-up and treatment must take safety of fetus into consideration

- Prolonged waiting period before subsequent pregnancy is not recommended
  - Consider factors that affect disease recurrence (thickness and stage), age and fertility
  - Delay is OK if patient waits for a year

- Approach melanocytic nevi in pregnant patients the same way with non-pregnant patients. If it needs to be done, it needs to be done.

- Exogenous hormones may be used in women with hx of MM

#ChooseKnowledge #POMA19

112

113

114
Post-lecture question #1

True or False:
Tanning booth use offers an effective means to increase a patient’s vitamin D levels.

Answer tally slide

10-15 minutes of incidental UVB exposure three times a week will usually maximize the skin’s active vitamin D production. (Tanning booths are predominantly UVA producers)
#2 True or False:

As a result of this lecture, I vow to take “a gander” at my patients’ back at least once a year.